CRSBP-1/LYVE-1 ligands stimulate contraction of the CRSBP-1-associated ER network in lymphatic endothelial cells  by Hou, Wei-Hsien et al.
FEBS Letters 586 (2012) 1480–1487journal homepage: www.FEBSLetters .orgCRSBP-1/LYVE-1 ligands stimulate contraction of the CRSBP-1-associated ER
network in lymphatic endothelial cells
Wei-Hsien Hou a, I-Hua Liua a, Shuan Shian Huang b, Jung San Huang a,⇑
aDepartment of Biochemistry and Molecular Biology, Saint Louis University School of Medicine, Doisy Research Center, 1100 S. Grand Blvd., St. Louis, MO 63104, United States
bAuxagen Inc., 7 Pricewoods LN, St. Louis, MO 63132, United States
a r t i c l e i n f o a b s t r a c tArticle history:
Received 19 March 2012
Accepted 3 April 2012
Available online 19 April 2012
Edited by Beat Imhof
Keywords:
LYVE-1
PDGF-BB
VEGF-A165
Hyaluronic acid
ER localization
ER contraction0014-5793/$36.00  2012 Federation of European Bio
http://dx.doi.org/10.1016/j.febslet.2012.04.001
⇑ Corresponding author. Address: Department of
Biology, St. Louis University School of Medicine, Doisy
1100 S. Grand Blvd., St. Louis, MO, 63104, Unites Stat
E-mail address: huangjs@slu.edu (J.S. Huang).CRSBP-l/LYVE-1 ligands (PDGF-BB,VEGF-A165 andhyaluronic acid)havebeen shownto induceopening
of lymphatic intercellular junctions in vitro and in vivo by stimulating contraction of lymphatic endo-
thelial cells (LECs). The mechanism by which CRSBP-1 ligands stimulate contraction of LECs is not
understood. Here we demonstrate that CRSBP-1 is localized to the plasmamembrane aswell as intra-
cellular ﬁbrillar structures in LECs, including primary human dermal LECs and SVEC4-10 cells. CRSBP-
1-associated ﬁbrillar structures are identical to the ER network as evidenced by the co-localization of
CRSBP-1 and BiP in these cells. CRSBP-1 ligands stimulate contraction of the ER network in a CRSBP-1-
dependent and paclitaxel (a microtubule-stabilizing agent)-sensitive manner. These results suggest
that ligand-stimulated ER contraction is associated with ligand-stimulated contraction in LECs.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction results suggest that CRSBP-1 and its ligands regulate the functionCell-surface retention sequence (CRS) binding protein-1
(CRSBP-1), a membrane glycoprotein, was identiﬁed by its ability
to interact with oligopeptides containing the CRS motifs of VEGF-
A165 and PDGF-BB in human SK-Hep cells and bovine liver plasma
membranes [1]. The CRS motifs of VEGF-A165 and PDGF-BB contain
clustered basic amino acid residues (Arg, Lys and His) [2–5].
CRSBP-1 interacts with PDGF-BB in simian sarcoma virus (SSV)-
transformed cells which express both CRSBP-1 and the autocrine
sis oncogene product (PDGF-BB) [6]. CRSBP-1 is identical to
lymphatic vessel endothelial hyaluronic acid (HA) receptor-1
(LYVE-1) [7–9]. The primary localization of LYVE-1 in lymphatic
endothelium implies the likely importance of the multiple ligand
(CRS-containing growth factors/cytokines and HA) binding activity
of CRSBP-1/LYVE-1 in regulating the function of lymphatic vessels.
To determine the in vivo role of CRSBP-1, we generated CRSBP-1-
null (CRSBP-1/) mice [10]. These mice are macroscopically
normal but exhibit distended lumens of lymphatic vessels and con-
stitutively increased transit of ﬂuid from the interstitial space into
lymphatic vessel lumens (termed interstitial-lymphatic transit).
CRSBP-1 ligands are capable of increasing interstitial-lymphatic
transit of ﬂuid in wild-type mice but not in CRSBP-1/mice. Thesechemical Societies. Published by E
Biochemistry and Molecular
Research Center, Room 413,
es. Fax: +1 314 977 9205.of lymphatic intercellular junctions. They also support our hypoth-
esis that the CRSBP-1-null mutation and binding of CRSBP-1 by its
cognate ligands cause opening of lymphatic intercellular junctions,
resulting in increased interstitial-lymphatic transit [10].
To determine the molecular mechanism by which CRSBP-1 and
its ligands regulate the opening of lymphatic intercellular junctions,
we investigated the effects of CRSBP-1 ligands on tyrosine phos-
phorylation and internalization of VE-cadherin, which forms but-
ton-like structures at lymphatic intercellular junctions [11] in
LECs.We hypothesized that the CRSBP-1-null mutation and binding
of CRSBP-1 by its cognate ligands would result in loss and ‘‘unbut-
toning’’ of VE-cadherin-mediated buttons, respectively, leading to
opening of lymphatic intercellular junctions [10,12]. We found that
CRSBP-1 ligands (PDGF-BB, VEGF-A165, PDGF peptide, VEGF peptide
and HA) stimulate tyrosine phophorylation of PDGF b-type recep-
tor/b-catenin/VE-cadherin, internalization of VE-cadherin and cel-
lular contraction in LEC monolayers [12]. This leads to opening of
lymphatic intercellular junctions. These CRSBP-1 ligand-stimulated
effects are abolished in LECs treated with a PDGF b-type receptor
(PDGFbR) kinase inhibitor or CRSBP-1 siRNA [12]. To determine
the role of CRSBP-1 in ligand-stimulated LEC contraction, we inves-
tigated the subcellular localization of CRSBP-1 in LECs, which in-
clude primary human dermal LECs (HDLECs) and SVEC4-10 cells
(a LEC-like cell line), treated with CRSBP-1 ligands. CRSBP-1 was
previously localized at the plasma membrane (or cell surface) of
CRSBP-1-transfected cells, SVEC4-10 cells and HDLECs by cell-sur-
face cross-linking with 125I-labeled speciﬁc peptide ligands oflsevier B.V. All rights reserved.
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In HDLECs, LYVE-1 was shown by Johnson et al. [13] to exhibit a
perinuclear staining pattern, co-localizing with markers of ER and
Golgi where its de novo synthesis occurs. The exact subcellular
localization of CRSBP-1/LYVE-1 in LECs is not clear.
In this communication, we demonstrate that CRSBP-1 is local-
ized to the plasma membrane as well as intracellular ﬁbrillar struc-
tures. The CRSBP-1-associated ﬁbrillar structure is identical to the
ER network, as evidenced by its co-localization with binding
immunoglobulin protein (BiP), an ER resident protein [14]. We also
show that CRSBP-1 ligands stimulate contraction of CRSBP-1-asso-
ciated ER network in a CRSBP-1-dependent and paclitaxel-
sensitive manner.2. Materials and methods
2.1. Materials
PDGF peptide (a 19-mer peptide containing the amino acid se-
quence YVRVRRPPKGKHRKFKHTH) and VEGF peptide (a 25-mer
peptide containing the amino acid sequence KKSVRGKGKGQKRKR
KKSRYKSWSV) were synthesized by C S Bio Co. (Menlo Park, CA).
Rabbit anti-CRSBP-1 antiserum was prepared as described [6,9,12].
PDGF-BB was obtained from Abeam Inc. (Cambridge, MA) and R&D
Systems (Minneapolis, MN). Anti-BiP/GRP78 antibody (sc-1051)
was obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).
VEGF-A165 was a gift fromDr. Daniel T. Connolly, Mosanto Company
(St. Louis, MO). Paclitaxel (T7402) and most of the biochemical re-
agents were obtained from Sigma (St. Louis, MO). H1299/CRSBP-1
and H1299/vector cells were prepared as described [9]. SVEC4-10
cells and human dermal LECs (HDLECs) were obtained from
American Type Culture Collection (Manassas, VA) and PromoCell
(Heidelberg, Germany), respectively.
2.2. Immunoﬂuorescence staining of CRSBP-1 and BiP in SVEC 4-10
cells and HDLECs
Cells grownoncoverslips for 2days (50%conﬂuence)were trea-
ted with CRSBP-1 ligands (10 lM PDGF peptide, 10 lM VEGF pep-
tide, 0.2 lM VEGF-A and 120 lg/ml HA) or vehicle only for 30 min
or 1 h in serum-free DMEM. After treatment, cells were ﬁrst washed
with PBS twice, and then ﬁxed in 100% methanol at 20 C for
10 min. Following rinsing with PBS, cells were quenched in 0.1% so-
dium borohydride in PBS for 5 min. Cells were washedwith PBS and
blocked with 0.2% gelatin in PBS at room temperature for 1 h. Cells
were incubated for 1 h with a 1:200 or 1:500 dilution of
anti-CRSBP-1 antiserum and anti-BiP antibody in a solution of 0.2%
gelatin in PBS, followed by incubationwith an 1:200 dilution of ﬂuo-
rescence-labeled secondary antibodies in a solution of 0.2% gelatin
in PBS for 1 h. Coverslips were then mounted on glass slides. The
slides were viewed under an Olympus AHBT3 ﬂuorescence micro-
scope using interference green ﬁlters. CRSBP-1 positive-associated
ﬁbrillar structureswere analyzed andquantiﬁed usingNIH software
Image J. Using the function ‘‘Auto-Threshold’’, a threshold valuewas
arbitrarily chosen to highlight positively-stained ﬁbrillar structures
in an image. Lengths of the ﬁbrillar structures of individual cells
were then determined using the function ‘‘Analyze Particle.’’ The
same threshold value was then used to analyze all images. A mini-
mumof25 cells fromeachconditionwasused for statistical analysis.
2.3. Immunoﬂuorescence confocal microscopy of the CRSBP-1/BiP
ﬁbrillar structures in LECs
SVEC4-10 cells and HDLECs were pretreated with paclitaxel
(5 lM) or vehicle only at 37 C for 2 h and then stimulated withCRSBP-1 ligands for 1 h and ﬁxed as previously described [12]. Fol-
lowing blocking, cells were incubated overnight at 4 C with rabbit
anti-CRSBP-1 serum and goat anti-BiP antibody at 1:200 dilution.
To estimate colocalization of CRSBP-1 and BiP in SVEC4-10 cells,
conﬂuent cells grown on coverslips were treated with CRSBP-1
ligands. Following ﬁxation and blocking, cells were incubated over-
night with rabbit anti-CRSBP-1 serum and goat antibody to BiP.
After extensive washing, cells were incubated with FITC-conju-
gated mouse anti-rabbit IgG antibody and rhodamine red-conju-
gated donkey anti-goat IgG antibody and at 1:200 dilution for
1 h. Images were acquired using a Leica TCS SP confocal micro-
scope (Leica Microsystems Ltd., Heidelberg, Germany).
2.4. siRNA transfection
Transfection of SVEC4-10 cells with control siRNA and CRSBP-1
siRNA was performed according to the manufacturer’s protocol
(Santa Cruz Biotechnology) as previously described [12]. Brieﬂy,
cells grown on coverslips were washed once with transfection
medium. Transfection medium (0.8 ml) (sc-36868) was added to
the cells. A 0.2 ml aliquot of transfection medium containing
80 pmoles CRSBP-1 siRNA (sc-42902) or control siRNA (sc-37007)
and 8 ll of transfection reagent (sc-29528) was incubated at room
temperature for 30 min before adding to the cells. Following 48 h
incubation at 37 C, transfected cells were washed and treated as
described before.
2.5. Statistical analysis
The values are presented as means ± S.D. (n = 3–5). Two-tailed
unpaired Student’s t-test was used to determine the signiﬁcance
of differences between groups. P < 0.05 was considered signiﬁcant.3. Results
3.1. CRSBP-1 localizes to the plasma membrane and intracellular
ﬁbrillar structures in LECs
CRSBP-1 is known to be a cell-surface membrane protein but its
subcellular localization in LECs has not been characterized. We
previously generated H1299/CRSBP-1 cells for studying the cell
biology of CRSBP-1 [9]. However, H1299 cells are a human lung
carcinoma cell line and are not an ideal cell system for investiga-
tion of such properties of CRSBP-1 because CRSBP-1 is primarily
localized to lymphatic capillary endothelial cells. For this reason,
we identiﬁed SVEC4-10 cells as a candidate cell system for study-
ing the cell biological functions of CRSBP-1. SVEC4-10 cells are a
SV40-immortalized endothelial cell line derived from mouse axil-
lary lymph nodes. These cells are thought to be derived from vas-
cular endothelial cells [15,16]. However, Western blot analysis of
SVEC4-10 cell revealed that they express CRSBP-1, podoplanin,
PDGFpR and VEGFR3 [12]. All of these proteins have been reported
to be speciﬁc markers for lymphatic capillary endothelial cells [17].
SVEC4-10 cells also exhibit ultrastructural features characteristic
of LECs including sparse microvillous surface projections, overlap-
ping intercellular junctions and abundant intermediate ﬁlaments
[16]. They are LEC-like cells.
To deﬁne the cell biological role of CRSBP-1, we examined sub-
cellular localization of CRSBP-1 in SVEC4-10 cells by immunolocal-
ization using rabbit antiserum to the cytoplasmic tail of CRSBP-1
(anti-CRSBP-1 serum) [6,9,12]. After ﬁxation and permeabilization
of SVEC4-10 cells, CRSBP-1 was visualized with ﬂuorescence
microscopy after incubation of the ﬁxed cells with preimmune
serum (Fig. 1, panel A), anti-CRSBP-1 serum (Fig. 1, panel B), or
anti-CRSBP-1 serum with 2 mM CRSBP-1 peptide antigen [1]
A B C
Fig. 1. CRSBP-1 is localized to the plasma membrane and intracellular ﬁbrillar structures in SVEC4-10 cells. Cells were grown on cover slips and ﬁxed with methanol at20 C
for 10 min. Cells were stained with preimmune serum (panel A), anti-CRSBP-1 antiserum (panels B) or anti-CRSBP-1 antiserum with 2 mM CRSBP-1 peptide antigen (panel C)
followed by FITC-conjugated goat anti-rabbit IgG and visualized with a ﬂuorescence microscope. Arrowheads indicate the plasma membrane localization of CRSBP-1. Data are
representative of four independent experiments.
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anti-rabbit IgG. As shown in Fig. 1 (panel B), CRSBP-1 is localized to
the plasma membrane and also to intracellular ﬁbrillar structures
in SVEC4-10 cells. The ﬁbrillar structures are not actin ﬁbers,
microtubules or intermediate ﬁlaments based on co-immunolocal-
ization experiments (data not shown). In these cells, CRSBP-1 is
associated with a ﬁbrillar network extending from the perinuclear
membrane to the leading edge of the plasma membrane (Fig. 1, pa-
nel B). The ﬁbrillar staining pattern truly represents the subcellular
localization of CRSBP-1 as the addition of CRSBP-1 peptide antigen
[1] completely abolished anti-CRSBP-1 serum binding to CRSBP-1
(Fig. 1, panel C).
3.2. CRSBP-1 ligands stimulate contraction of CRSBP-1-associated
intracellular ﬁbrillar structures in a time-dependent manner in LECs
To determine the functional signiﬁcance of the association of
CRSBP-1 with the ﬁbrillar structures, we determined the effects
of CRSBP-1 ligands (VEGF peptide and HA) on the CRSBP-1-associ-
ated ﬁbrillar structures in SVEC4-10 cells. VEGF peptide, a 25-mer
peptide containing the CRS motif of VEGF-A165, is a speciﬁc CRSBP-
1 ligand which does not interact with VEGFR2 [1]. The cells were
treated with VEGF peptide (2 lM) or HA (100 lg/ml). After 2 h at
37 C, the cells were ﬁxed with methanol at 20 C for 10 min
and stained with anti-CRSBP-1 serum followed by FITC-conjugated
goat anti-rabbit IgG. In cells treated with VEGF peptide (Fig. 2), the
ﬁbrillar structures became contracted as compared with the same
structures in cells treated with vehicle only (Fig. 2, panel D vs. pa-
nel C). HA, also a ligand for CRSBP-1, exhibited moderate effects on
the morphology of SVEC4-10 cells, causing them to assume a spin-
dle (ﬁbroblast-like) appearance which was due to changes in the
CRSBP-1-associated ﬁbrillar structures (Fig. 2, panel E). However,
the effects of both HA and VEGF peptide were abolished when cells
were co-treated with HA and VEGF peptide (Fig. 2, panel F). The
mechanism for this effect of co-treatment with HA and VEGF pep-
tide is unknown, but VEGF peptide is known not to affect HA bind-
ing to CRSBP-1 [9]. This is likely due to an allosteric effect. The HA
and CRS motif binding sites are located at distinct sites: the Link
module (amino acid residues 54–130) and the acidic-amino-acid-
rich region (amino acid residues 204–229), respectively, in human
CRSBP-1 [18].
To determine the functional signiﬁcance of the contraction of
CRSBP-1-associated ﬁbrillar structures in SVEC4-10 cells, we
examined the time dependence of the effects of CRSBP-1 ligands
(PDGF peptide, VEGF peptide and HA) on CRSBP-1-associated ﬁbril-
lar structures. PDGF peptide, a 19-mer peptide containing the CRS
motif of PDGF-BB, is a speciﬁc CRSBP-1 ligand and does not interact
with the PDGF b-type receptor (PDGFbR) [1,9]. SVEC4-10 cells were
treated with PDGF peptide (10 lM), VEGF peptide (10 lM), or HA
(100 lg /ml). After 0 h, 0.5 h, 1 h, and 2 h at 37 C, the cells were
ﬁxed with methanol at 20 C for 20 min and stained with rabbitantiserum to CRSBP-1 and rhodamine red-conjugated goat anti-
rabbit IgG. The CRSBP-1-associated ﬁbrillar structures appeared
to be relatively stable and did not show any morphological changes
after incubation with vehicle only at 37 C for 2 h (Fig. 3, panel D
vs. panel A). However, PDGF peptide, VEGF peptide and HA all
stimulated maximal contraction of the ﬁbrillar structures in
SVEC4-10 cells after a 30-min incubation at 37 C (Fig. 3, panels,
F, J and N, respectively). CRSBP-1 ligand-stimulated contraction
of the CRSBP-1-associated ﬁbrillar structures was then quantiﬁed.
As shown in Fig. 4 (panel A), PDGF peptide at 10 lM for 0.5 h stim-
ulated contraction of the ﬁbrillar structures by 70%. Treatments
with VEGF peptide (10 lM) and HA (100 lg/ml) for 0.5 h caused
contraction of the ﬁbrillar structures by 40% and 30%, respec-
tively (Fig. 4, panels B and C).
3.3. CRSBP-1 ligands stimulate contraction of the CRSBP-1-associated
ER network in LECs
Since immunostaining of CRSBP-1 does not colocalize with that
of any of the known cytoskeleton proteins and since the CRSBP-
1-associated ﬁbrillar structures include the perinuclear membrane
which is known to be associated with the endoplasmic reticulum
(ER) network, we hypothesized that CRSBP-1-associated ﬁbrillar
structures are identical to the ER network. To test this hypothesis,
we determined the co-localization of CRSBP-1 and BiP, which is a
heat shock protein and a speciﬁc marker for the ER [14], using indi-
rect immunoﬂuorescence staining and confocal microscopy. As
shown in Fig. 5A, the CRSBP-1-associated ﬁbrillar structures co-
localize with the staining pattern of BiP (panels A, B and C). While
the immunostaining pattern of BiP lacked the plasma-membrane
distribution, the intracellular staining pattern of BiP was com-
pletely identical to that of CRSBP-1 (panels C, F, I, L and O). To
determine the effects of CRSBP-1 ligands on the CRSBP-1-associ-
ated ER network, SVEC4-10 cells were stimulated with 10 lM
VEGF peptide, 10 lM PDGF peptide, 5 nM VEGF-A165, and 100 lg/
ml HA. As shown in Fig. 5 A, VEGF peptide (panels D, E and F), PDGF
peptide (panels G, H and I), VEGF-A165 (panels J, K and L), and HA
(panels M, N and O) stimulated contraction of the CRSBP-1-associ-
ated ER network when compared to vehicle only-treatment (panels
A, B and C). VEGF-A165 is a putative physiological CRSBP-1 ligand
for LECs which express very little endogenous VEGFR2, a speciﬁc
receptor for VEGF-A165 in blood vascular endothelial cells
[5,19,20]. These results suggest that CRSBP-1 ligands are capable
of stimulating contraction of the CRSBP-1-associated ER network
in SVEC4-10 cells.
As described above, SVEC4-10 cells are SV40-transformed LECs
[16]. To determine if CRSBP-1 ligand-stimulated effects observed in
SVEC4-10 cells also occur in normal LECs, we performed the same
set of experiments using primary-culture HDLECs isolated from
human skin (PromoCell C-12216). HDLECs grown on coverslips
were stimulated with 10 lM VEGF peptide, 10 lM PDGF peptide,
A B
C D 
E F 
Fig. 2. CRSBP-1 ligands stimulate contraction of CRSBP-1-associated ﬁbrillar structures in SVEC4-10 cells. Cells were seeded on Petri dishes (panel B) and cover slips (panels
A, C, D, E and F). Cells were treated with vehicle only (panels A, B and C), VEGF-A peptide (10 lM) (panel D), HA (100 lg/ml) (panel E) or HA (100 lg/ml) plus VEGF-A peptide
(10 lM) (panel F). After 2 h at 37 C, cells were ﬁxed with paraformaldehyde and then permeabilized by acetone (panel B) or ﬁxed and permeabilized with methanol at20 C
for 10 min (panels A, C, D, E and F). CRSBP-1 was stained with anti-CRSBP-1 antiserum (panels B, C, D, E and F) or preimmune serum panel (panel A) followed by FITC-
conjugated goat anti-rabbit IgG and visualized with a ﬂuorescence microscope. The bar indicates a scale of 10 lm (panel A). The arrow in (panel B) indicates the edge of the
plasma membrane. Control staining (with preimmune serum) of cells treated with CRSBP-1 ligands were negative like (panel A) (data not shown). Data are representative of
ﬁve independent experiments.
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noﬂuorescence staining of stimulated cells using anti-CRSBP-1 ser-
um and antibody to BiP followed by confocal microscopy analysis
revealed intracellular co-localization of CRSBP-1 with BiP in the
ER network of HDLECs as shown in Fig. 5B. As seen in SVEC4-10
cells, CRSBP-1 ligands stimulated contraction of the CRSBP-1-asso-
ciated ER network in HDLECs (panels F, I, L, O and R). PDGF-BB
(panels M, N and O) and HA (panels P, Q and R) caused less contrac-
tion of the CRSBP-1-associated ER network in HDLECs than PDGF
peptide (panels D, E and F), VEGF peptide (panels G, H and I) or
VEGF-A165 (panels J, K and L). VEGF-A165 contains the putative
CRS motif [1,5,19,20]. These results suggest that CRSBP-1 is local-
ized to the plasma membrane and the ER network in mouse and
human LECs and that CRSBP-1 ligands stimulate contraction of
the CRSBP-1-associated ER network in both cell types.
3.4. CRSBP-1 ligands stimulate contraction of the CRSBP-1-associated
ER network in a CRSBP-1-dependent manner in SVEC4-10 cells
To test the involvement of CRSBP-1 in ligand-stimulated con-
traction of the ER network, SVEC4-10 cells were transfected with
control siRNA or CRSBP-1 siRNA as described previously [12].
These transfected cells were then treated with 10 lM of PDGF
peptide or VEGF peptide for 1 h and then analyzed by indirect
immunoﬂuorescence staining using antiserum to CRSBP-1 andantibody to BiP. As shown in Fig. 6, cells transfected with control
siRNA, like untransfected cells, exhibited responses to ligand-
stimulated contraction of the CRSBP-1-associated ER network
(panels D, E, F and panels G, H, I vs. panels A, B, C). However,
down-regulation of CRSBP-1 expression by transfection of cells
with CRSBP-1 siRNA abolished such ligand-stimulated contraction
(Fig. 6, panels M, N, O and P, Q, R vs. panels J, K, L). Under the stated
conditions [12], at 48 h after CRSBP-1 siRNA transfection, CRSBP-1
protein levels were down-regulated by 80% compared with levels
in cells transfected with control siRNA. Interestingly, down-
regulation of CRSBP-1 proteins by CRSBP-1 siRNA transfection also
led to constitutive contraction of the ER network (panels J to R vs.
panels A, B and C). These results suggest that CRSBP-1 is required
for ligand-stimulated contraction of the ER network in SVEC4-10
cells. These results are also comparable to our recent ﬁndings that
CRSBP-1 siRNA transfection abolishes ligand-stimulated perme-
ability in SVEC4-10 cell monolayers and that down-regulation of
CRSBP-1 protein by CRSBP-1 siRNA transfection leads to constitu-
tively increased permeability in these cells [12].
3.5. Paclitaxel blocks ligand-stimulated contraction of the CRSBP-1-
associated ER network in SVEC4-10 cells
Rearrangement (polymerization and de-polymerization) of
cytoskeletal proteins (e.g., microtubules) is usually involved in
HA
100 µg/ml
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10 µM 
0.5 h 1h 2h
VEGF-
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10 µM 
Control
0 h
A B C D 
E F G H 
I J K L 
M P N O 
Fig. 3. CRSBP-1 ligands stimulate contraction of CRSBP-1-associated ﬁbrillar structures in a time-dependent manner in SVEC4-10 cells. Cells were seeded on coverslips and
treated with vehicle only (panels A to D), 10 lM PDGF peptide (panels E to H), 10 lM VEGF peptide (panels I to L), or 100 lg/ml HA (panels M to P) for 0 min, 0.5 h, 1 h, and
2 h. After incubation, cells were ﬁxed with methanol at 20 C for 10 min. Cells were stained with anti-CRSBP-1 serum followed by rhodoamine red-conjugated goat anti-
rabbit IgG and visualized with a ﬂuorescence microscope. The bar indicates a scale of 10 lm (panel A). Data are representative of four independent experiments.
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Fig. 4. PDGF peptide, VEGF peptide and HA quantitatively stimulate contraction of CRSBP-1-associated ﬁbrillar structures in SVEC4-10 cells. Cells were stimulated with
vehicle only, 10 lM PDGF peptide (panel A), 10 lM VEGF peptide (panel B) and 100 lg/ml HA (panel C). Lengths of the CRSBP-1-associated ﬁbrillar structures shown in Fig. 3
were quantiﬁed using the program NIH Image J. A minimum of 25 cells were examined for each experimental group. The same threshold was used for analysis in each group.
The bar represents mean ± S.D. ⁄Signiﬁcantly lower than the vehicle control (q < 0.05). Data are representative of three independent experiments.
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ﬁbrillar network is associated with contraction of microtubules
[21–24]. We hypothesize that CRSBP-1 ligand-induced contraction
of the ER network is associated with CRSBP-1 ligand-stimulated
cellular contraction in LECs. To test this, we determined the effect
of paclitaxel [25], a microtubule polymer stabilizer, on CRSBP-1 li-gand-induced ER network contraction in SVEC4-10 cells. Cells were
pretreated with paclitaxel or vehicle only at 37 C for 1 h and then
stimulated with 10 lM PDGF peptide or VEGF peptide for 1 h.
These stimulated cells were then analyzed by indirect immunoﬂu-
orescence staining using antibodies to CRSBP-1 and BiP. As shown
in Fig. 7, paclitaxel blocked the CRSBP-1 ligand-induced
Control
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peptide
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HA 
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Fig. 5. CRSBP-1 ligands stimulate contraction of the CRSBP-1-associated ER network in SVEC4-10 cells (A) and HDLECs (B). (A) SVEC4-10 cells were seeded on coverslips and
treated with vehicle only (panels A, B and C), 10 lM VEGF peptide (panels D, E and F), 10 lM PDGF peptide (panels G, H and I), 100 ng/ml VEGF-A165 (panels J, K and L) or
100 lg/ml HA (panels M, N and O) for 1 h. After incubation, cells were ﬁxed with methanol at 20 C for 10 min. Cells were stained with anti-CRSBP-1 serum (panels A, D, G, J
and M) and anti-BiP (the ER marker) antibody (panels B, E, H, K and N), then visualized with a confocal microscope. Cells treated with vehicle only and CRSBP-1 ligands
showed intracellular co-localization of CRSBP-1 and BiP (panels C, F, I, L and O). The bar indicates a scale of 10 lm (panel A). CRSBP-1 ligand treatment induced contraction of
the CRSBP-1-associated ER network in SVEC4-10 cells. Arrowheads indicate the plasma membrane localization of CRSBP-1. Data are representative of four independent
experiments. (B) HDLECs were seeded on coverslips and treated with vehicle only (control) (panels A, B and C), 10 lM PDGF peptide (panels D, E and F), 10 lM VEGF peptide
(panels G, H and I), 100 ng/ml VEGF-A165 (panels J, K and L), 50 ng/ml PDGF-BB (panels M, N and O) or 100 lg/ml HA (panels P, Q and R) for 1 h. After incubation, cells were
ﬁxed with methanol at 20 C for 10 min. Cells were stained with anti-CRSBP-1 serum (panels A, D, G, J, M and P) and anti-BiP (ER marker) antibody (panels B, E, H, K, N and
Q) and visualized with a confocal microscope. Cells treated with vehicle only and the same agents showed intracellular co-localization of CRSBP-1 and BiP (panels C, F, I, L, O
and R). PDGF peptide, VEGF peptide,VEGF-A, PDGF-BB and HA treatment stimulated contraction of the CRSBP-1-associated ER network in HDLECs (panels F, I, L, O and R). The
bar indicates a scale of 10 lm (panel A). Arrowheads indicate the plasma membrane distribution of CRSBP-1. Data are representative of four independent experiments.
W.-H. Hou et al. / FEBS Letters 586 (2012) 1480–1487 1485contraction of the ER network in these cells (panels M, N, O and
panels P, Q, R vs. panels D, E, F and panels G, H, I). Paclitaxel alone
did not affect the ER network (panels J, K and L vs. panels A, B and
C). These results suggest that PDGF peptide and VEGF peptide
stimulate contraction of the ER network in SVEC4-10 cells in a pac-
litaxel-sensitive manner.
4. Discussion
The subcellular localization of CRSBP-1 in the plasma mem-
brane and ER network suggests a unique property of CRSBP-1.
Many type I membrane proteins are mainly localized in the plasma
membrane and are not detected in the ER even though they trafﬁc
through it to the plasma membrane after synthesis. The ER reten-
tion mechanism of CRSBP-1 is unknown. CRSBP-1 does not contain
the C-terminal di-lysine or di-arginine motif which has been
shown to mediate ER retention of type I membrane proteins [26].
However, it contains a basic amino acid-rich motif (KSPSKTTVR)
near its C-terminus. This motif is well conserved in all known
mammalian CRSBP-1 congeners and may play a role in the ER
localization of mammalian CRSBP-1 congeners (human, bovine
and mouse). The functional signiﬁcance of ER localization of
CRSBP-1 in ligand-stimulated contraction of LECs is not known.
Several lines of evidence indicate that ER localization of CRSBP-1plays an important role in CRSBP-1 ligand-stimulated LEC contrac-
tion. These include: (1) CRSBP-1 ligands are unable to stimulate
detectable contraction in SSV-transformed cells and H1299/
CRSBP-1 cells, both of which express CRSBP-1 but do not exhibit
the ER localization of CRSBP-1 [6,9]. (2) A speciﬁc kinase activity
inhibitor of PDGFbR, which is a signaling partner of CRSBP-1, inhib-
its CRSBP-1 ligand-stimulated contraction in LECs [12]. This
suggests that CRSBP-1 ligand-stimulated contraction of the
CRSBP-1-associated ER network is a downstream effect of the
CRSBP-1-PDGFbR-mediated signaling [12] and (3) Contraction of
the ER network is known to be associated with morphological
changes in cells [23,24]. The localization and abundance of
CRSBP-1 at both the plasma membrane and ER may explain why
lymphatic endothelium in tissues can be strongly stained histo-
chemically by anti-CRSBP-1 antibody.
The CRSBP-1 ligand-induced contraction of the ER network ap-
pears to be mediated by microtubules as evidenced by the observa-
tion that paclitaxel, a microtubule polymer stabilizer, effectively
blocks CRSBP-1 ligand-induced contraction of the ER network.
Since microtubule contraction is commonly associated with
morphological changes in cells [21–24], we predicted that
CRSBP-1 ligand-induced contraction of the ER network in SVEC4-
10 cells and HDLECs would result in morphological changes in
these cells. As predicted, we found that CRSBP-1 ligand stimulation
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Fig. 6. CRSBP-1 ligands stimulate contraction of the CRSBP-1-associated ER
network in SVEC4-10 cells in a CRSBP-1-dependent manner. Cells transfected with
control siRNA (panels A to I) and CRSBP-1 siRNA (panels J to R) were stimulated
with vehicle only (panels A, B, C and panels J, K, L), 10 lM PDGF peptide (panels D, E,
F and panels M, N, O) and 10 lM VEGF A peptide (panels G, H, I and panels P, Q, R)
for 1 h. After stimulation, cells were ﬁxed with methanol at 20 C for 10 min and
stained with anti-CRSBP-1 serum (panels A, D, G, J, M and P) and anti-BiP (the ER
marker) antibody (panels B, E, H, K, N and Q), then visualized with a confocal
microscope. Cells treated with vehicle only and CRSBP-1 ligands showed intracel-
lular co-localization of CRSBP-1 and BiP (panels C, F, I, L, O and R). As described
previously (12), about 80% of CRSBP-1 protein was down-regulated by transfection
of SVEC4-10 cells with CRSBP-1 siRNA compared with those of cells transfected
with control siRNA. CRSBP-1 ligands stimulated contraction of the ER network in
cells transfected with control siRNA (panels D to I vs. panels A, B and C). Down
regulation of CRSBP-1 protein by CRSBP-1 siRNA transfection abolished CRSBP-1
ligand-stimulated contraction of the ER network in these cells (panels M to R vs.
panels J, K and L). Cells transfected with CRSBP-1 siRNA exhibited constitutive
contraction of the ER network (panels J to R vs. panels A, B and C). Arrowheads
indicate the plasma membrane localization of CRSBP-1.
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1486 W.-H. Hou et al. / FEBS Letters 586 (2012) 1480–1487does result in morphological (opening of intercellular junctions)
and functional changes (increased permeability) at intercellular
junctions in these LEC monolayers. The ﬁnding of paclitaxel as a
potent inhibitor for CRSBP-1 ligand-stimulated contraction of
CRSBP-1 ligand-associated ER network (and likely for CRSBP-1 li-
gand-stimulated opening of lymphatic intercellular junctions as
well) [12] has potentially important clinical implications. Physio-
logical CRSBP-1 ligands (e.g., PDGF-BB) are hypothesized to be uti-
lized by carcinoma cells in the interstitial space of tissues to enter
lymphatic vessel lumens by inducing opening of lymphatic inter-
cellular junctions during lymphatic metastasis. Paclitaxel and
related compounds may prevent lymphatic metastasis in certain
human cancers (e.g., lung cancer) [27] by blocking CRSBP-1
ligand-induced opening of lymphatic intercellular junctions.
Johnson et al. [13] demonstrated that most of the LYVE-1 (or
CRSBP-1) intracellular staining is lost upon stimulation of HDLECs
with TNF-a. This raises the possibility that CRSBP-1 ligands might
induce contraction (or shortening) of CRSBP-1-asosciated ERF
ﬁ
(D
w
F
st
w
(pnetwork by down-regulating the cell-surface and intracellular lev-
els of CRSBP-1, by analogy to the effect of TNF-a. However, we
found that treatment with CRSBP-1 ligands does not diminish the
cell-surface and total protein levels of CRSBP-1 in SVEC4-10 cells
[28]. In contrast, TNF-a completely down-regulates cell-surface
expression of CRSBP-1 in SVEC4-10 cells [28], as reported by John-
son et al. in HDLECs [13]. These results suggest that the effects of
CRSBP-1 ligands on CRSBP-1/LYVE-1 expression are distinct from
those of TNF-a in LECs. Here we demonstrate that down-regulation
of CRBP-1 protein by transfection with CRSBP-1 siRNA abolishes
lignd-stimulated contraction of the ER network in SVEC4-10 cells
and that these cells transfected with CRSBP-1 siRNA exhibit consti-
tutive contraction of the ER network. Together with previous
observations [10,12], these results suggest that CRSBP-1 ligands
stimulate contraction of the ER network and LECs in a CRSBP-
1-dependent manner, resulting in opening of lymphatic intercellu-
lar junctions. This leads to increased permeability in LEC monolay-
ers in vitro and increased interstitial-lymphatic transit in whole
animals. Down-regulation of CRSBP-1 protein by transfection of
cells with CRSBP-1 siRNA and CRSBP-1-null mutation in mice cause
constitutive contraction of LECs and constitutively increased
permeability in LEC monolayers, and formation of distended
lymphatic vessel lumens (opening) and constitutive increase in
interstitial-lymphatic transit in whole animals, respectively
[10,12]. LYVE-1 (CRSBP-1) is involved in the formation of VE-
cadherin-mediated ’’button’’-like structures at lymphatic intercel-
lular junctions [11]. These results also support the hypothesis that
W.-H. Hou et al. / FEBS Letters 586 (2012) 1480–1487 1487CRSBP-1 siRNA transfection/CRSBP-1-null mutation and binding of
CRSBP-1 by its cognate ligands result in loss and ‘‘unbuttoning’’
of VE-cadherin-mediated buttons, respectively, leading to opening
of lymphatic intercellular junctions [10,12].
Acknowledgments
We thank Frank E. Johnson, M.D. for critically reviewing the
manuscript and Thomas Heyduk, Ph.D. for providing assistance in
confocal ﬂuorescence microscopy. This work was supported by
NIH grants HL 095261 and AR 052578 to Auxagen and
AAO19233 to St. Louis University (J.S.H.).
References
[1] Boensch, C., Kuo, M.D., Connolly, D.T., Huang, S.S. and Huang, J.S. (1995)
Identiﬁcation, puriﬁcation and characterization of cell-surface retention
sequence-binding proteins from human SK-Hep cells and bovine liver
plasma membranes. J. Biol. Chem. 270, 1807–1816.
[2] LaRochelle, W.J., May-Siroff, M., Robbins, K.C. and Aaronson, S.A. (1991) A
novel mechanism regulating growth factor association with the cell surface:
identiﬁcation of a PDGF retention domain. Genes Dev. 5, 1191–1199.
[3] Ostman, A., Andersson, M., Betsholtz, C., Westermark, B. and Heldin, C.-H.
(1991) Identiﬁcation of a cell retention signal in the B-chain of platelet-
derived growth factor and in the long splice version of the A-chain. Cell Regul.
2, 503–512.
[4] Joukov, V., Sorsa, T., Kumar, V., Jeltsch, M., Claesson-Welsh, L., Cao, Y., Saksel,
O., Kalkkinen, N. and Alitalo, K. (1997) Proteolytic processing regulates
receptor speciﬁcity and activity of VEGF-C. EMBO J. 16, 3898–3911.
[5] Carmeliet, P., Ng, Y.S., Nuyens, D., Theilmeier, G., Brusselmans, K., Cornelissen,
I., Ehler, E., Kakkar, V.V., Stalmans, I., Mattot, V., Nuyens, D., Lutgens, E.,
Clotman, R., de Ruiter, M.C., Gittenberger-de Groot, A., Poelmann, R., Lupu, F.,
Herbert, J.M., Collen, D. and Dejana, E. (1999) Impaired myocardial
angiogenesis and ischemic cardiomyopathy in mice lacking the vascular
endothelial growth factor isoforms VEGF164 and VEGF188. Nat. Med. 5, 495–
502.
[6] Boensch, C., Huang, S.S., Connolly, D.T. and Huang, J.S. (1999) Cell surface
retention sequence binding protein-1 interacts with the v-sis gene product
and platelet-derived growth factor beta-type receptor in simian sarcoma
virus-transformed cells. J. Biol. Chem. 274, 10582–10589.
[7] Banerji, S., Ni, J., Wang, S.X., Clasper, S., Su, J., Tammi, R., Jones, M. and Jackson,
D.G. (1999) LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-
speciﬁc receptor for hyaluronan. J. Cell Biol. 144, 789–801.
[8] Prevo, R., Banerji, S., Ferguson, D.J., Clasper, S. and Jackson, D.G. (2001) Mouse
LYVE-1 is an endocytic receptor for hyaluronan in lymphatic endothelium. J.
Biol. Chem. 276, 19420–19430.
[9] Huang, S.S., Tang, F.M., Huang, Y.H., Liu, I.-H., Hsu, S.C., Chen, S.T. and Huang,
J.S. (2003) Cloning, expression, characterization, and role in autocrine cell
growth of cell surface retention sequence binding protein-1. J. Biol. Chem. 278,
43855–43869.
[10] Huang, S.S., Liu, I.-H., Smith, T., Shah, M.R., Johnson, F.E. and Huang, J.S. (2006)
CRSBP-1/LYVE-l-null mice exhibited identiﬁable morphological and functional
alterations of lymphatic capillary vessels. FEBS Lett. 580, 6259–6268.[11] Baluk, P., Fuxe, J., Hashizume, H., Romano, T., Lashnits, E., Butz, S., Vestweber,
D., Corada, M., Molendini, C., Dejana, E. and McDonald, D.M. (2007)
Functionally specialized junctions between endothelial cells of lymphatic
vessels. J. Exp. Med. 204, 2349–2362.
[12] Hou, W.-H., Liu, I.-H., Tsai, C.C., Johnson, F.E., Huang, S.S. and Huang, J.S. (2011)
CRSBP-l/LYVE-1 Ligands induce disruption of lymphatic intercellular adhesion
by inducing tyrosine phosphorylation and internalization of VE-cadherin. J.
Cell Sci. 124, 1231–1244.
[13] Johnson, L.A., Prevo, R., Clasper, S. and Jackson, D.G. (2007) Inﬂammation-
induced uptake and degradation of the lymphatic endothelial hyaluronan
receptor LYVE-1. J. Biol. Chem. 282, 33671–33680.
[14] Shen, J., Chen, X., Hendershot, L. and Prywes, R. (2002) ER stress regulation of
ATF6 localization by dissociation of BiP/GRP78 binding and unmasking of
Golgi localization signals. Dev. Cell. 3, 99–111.
[15] Gavard, J. and Gutkind, J.S. (2006) VEGF controls endothelial-cell permeability
by promoting the beta-arrestin-dependent endocytosis of VE-cadherin. Nat.
Cell Biol. 8, 1223–1234.
[16] O’Connell, K.A. and Edidin, M. (1990) A mouse lymphoid endothelial cell line
immortalized by simian virus 40 binds lymphocytes and retains functional
characteristics of normal endothelial cells. J. Immunol. 144, 521–525.
[17] Kato, S., Shimoda, H., Ji, R.C. and Miura, M. (2006) Lymphangiogenesis and
expression of speciﬁc molecules as lymphatic endothelial cell markers. Anat.
Sci. Int. 81, 71–83.
[18] Chen, W.-H., Tseng, W.-R, Lin, G.-H., Huang, R.W., Schreiner, Chen, H.-R., Voigt,
M.-M., Yuh, C.-H., Wu, J.-L., Huang, S.S. and Huang, J.S. (submitted for
publication) The ortholog of LYVE-1 is required for thoracic duct formation in
zebraﬁsh.
[19] Houck, K.A., Ferrara, N., Winer, J., Cachianes, G., Li, B. and Leung, D.W. (1991)
The vascular endothelial growth factor family: identiﬁcation of a fourth
molecular species and characterization of alternative splicing of RNA. Mol.
Endocrinol. 5, 1806–1814.
[20] Ferrara, N. (2004) Vascular endothelial growth factor: basic science and
clinical progress. Endocr. Rev. 25, 581–611.
[21] Lee, C. and Chen, L.B. (1988) Dynamic behavior of endoplasmic reticulum in
living cells. Cell 54, 37–46.
[22] Allan, V.J. and Vale, R.D. (1991) Cell cycle control of microtubule-based
membrane transport and tubule formation in vitro. J. Cell Biol. 113, 347–359.
[23] Terasaki, M., Chen, L.B. and Fujiwara, K. (1986) Microtubules and the
endoplasmic reticulum are highly interdependent structures. J. Cell Biol.
103, 1557–1568.
[24] Waterman-Storer, C.M. and Salmon, E.D. (1998) Endoplasmic reticulum
membrane tubules are distributed by microtubules in living cells using
three distinct mechanisms. Curr. Biol. 8, 798–806.
[25] Bollag, D.M., McQueney, P.A., Zhu, J., Hensens, O., Koupal, L., Liesch, J., Goetz,
M., Lazarides, E. and Woods, C.M. (1995) Epothilones, a new class of
microtubule-stabilizing agents with a taxol-like mechanism of action.
Cancer Res. 55, 2325–2333.
[26] Pagny, S., Lerouge, P., Faye, L. and Gomord, V. (1999) Signals and mechanisms
for protein retention in the endoplasmic reticulum. J. Exp. Bot. 50, 157–164.
[27] Liu, J., Meisner, D., Kwong, E., Wu, X.Y. and Johnston, M.R. (2009)
Translymphatic chemotherapy by intrapleural placement of gelatin sponge
containing biodegradable paclitaxel colloids controls lymphatic metastasis in
lung cancer. Cancer Res. 69, 1174–1181.
[28] Chen,Hsiao-Rong. (2009) Role of CRSBP-1 in regulation of cell migration in
lymphatic endothelial cells and its orthologue in zebraﬁsh. Master thesis.
Institute of Systems Biology and Bioinformatics, National Central University,
Choungli, Taiwan.
